Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149811 · ClinicalTrials.gov registry record
A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease
A clinical trial, sponsored by Bausch Health Americas.
- Completed
- Registry status
- 27
- Enrollment target
NCT01149811: Completed study, sponsored by Bausch Health Americas.
NCT01149811 is a clinical trial that has completed, run by Bausch Health Americas. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01149811 has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to compare the safety and tolerability of two dose regimens of fipamezole in adult patients with Parkinson's Disease who are receiving levodopa.
Primary Outcome
Safety will be evaluated by assessing adverse events (AEs), vital signs (supine and orthostatic systolic and diastolic blood pressure, radial pulse rate), 12-lead ECG, blood and urine laboratory panels, and physical examination. Signs and symptoms of Parkinson's disease will be assessed using Hoehn and Yahr scale during the 'on' state.
Interventions
- DRUG Fipamezole ODT
- DRUG Fipamezole ODT Cohort 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-07 |
| Est. Completion | 2010-11 |
What the finished NCT01149811 record still lists
NCT01149811 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Fipamezole ODT is the first listed.
NCT01149811 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01149811 about?
NCT01149811 is a clinical study titled "A Study Comparing the Safety and Tolerability of Two Doses of Fipamezole in Adult Patients With Parkinson's Disease". The purpose of this clinical trial is to compare the safety and tolerability of two dose regimens of fipamezole in adult patients with Parkinson's Disease who are receiving levodopa.
What is the current status of trial NCT01149811?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2010-07. Estimated completion is 2010-11.
What interventions are being tested in trial NCT01149811?
The interventions under investigation include: Fipamezole ODT (DRUG), Fipamezole ODT Cohort 2 (DRUG).
Who is sponsoring clinical trial NCT01149811?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia